In this study, we enrolled 30 CN-AML patients with poor survival and selected 30 cases with long-term survival by matching the well-established factors such as age, WBC, and mutations in FLT3-ITD, CEBPA, NPM1, DNMT3A, IDH1, and IDH2 genes. This evidence concerns the gene DNMT3A and acute myeloid leukemia.